Flávio Signorelli
YOU?
Author Swipe
View article: Predictors of Mortality in Antiphospholipid Antibody–Positive Patients: Prospective Results From Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository
Predictors of Mortality in Antiphospholipid Antibody–Positive Patients: Prospective Results From Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository Open
Objective The objective was to determine the mortality rate as well as the causes and predictors of death in antiphospholipid antibody (aPL)–positive patients with and without antiphospholipid syndrome (APS) classification. Methods The inc…
View article: Patients with DVT and primary antiphospholipid syndrome have worse obstetric outcomes than pregnant women with DVT and negative antiphospholipid antibodies: a retrospective cohort study
Patients with DVT and primary antiphospholipid syndrome have worse obstetric outcomes than pregnant women with DVT and negative antiphospholipid antibodies: a retrospective cohort study Open
BACKGROUND: Pregnant women are at an increased risk of thromboembolism compared with non-pregnant women. Venous thrombosis is a manifestation of antiphospholipid syndrome (APS), an autoimmune thrombophilia associated with pregnancy morbidi…
View article: Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry Open
Objectives Our primary objective was to quantify damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis in an international cohort (the APS ACTION cohor…
View article: COMPARISON OF SINGLE LUPUS ANTICOAGULANT POSITIVITY VERSUS TRIPLE POSITIVITY IN PRIMARY ANTIPHOSPHOLIPID SYNDROME PATIENTS
COMPARISON OF SINGLE LUPUS ANTICOAGULANT POSITIVITY VERSUS TRIPLE POSITIVITY IN PRIMARY ANTIPHOSPHOLIPID SYNDROME PATIENTS Open
CONCLUSIONLA single positivity may represent a high-risk phenotype comparable to triple-positivity and could be used as a disease severity surrogate marker.
View article: CUTANEOUS MANIFESTATIONS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS) BEWARE OF LIVEDO RETICULARIS
CUTANEOUS MANIFESTATIONS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS) BEWARE OF LIVEDO RETICULARIS Open
CONCLUSIONCutaneous findings are common in PAPS patients, mainly RF and LR.Migraine and Caucasians are related to LR. Patients with LR are at higher risk of arterial events, with a chance greater than 3 times of presenting with stroke.
View article: EVALUATION OF THE QUALITY OF ANTICOAGULATION IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME TREATED WITH WARFARIN
EVALUATION OF THE QUALITY OF ANTICOAGULATION IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME TREATED WITH WARFARIN Open
Antiphospholipid Syndrome (APS) is a multisystem autoimmune disorder characterized by recurrent thrombotic events.Lifelong anticoagulation with vitamin K antagonists is the mainstay of APS treatment.Time in Therapeutic Range (TTR) is a met…
View article: Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome Open
Objective Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency of antiphospholipid antibodies (aPL). Recent reports of thrombosis associated with adenovirus-based vaccines raised concern that SARS-CoV…
View article: Immunogenicity, Safety and Antiphospholipid Antibodies After SARS-CoV-2 Vaccine in Patients With Primary Antiphospholipid Syndrome
Immunogenicity, Safety and Antiphospholipid Antibodies After SARS-CoV-2 Vaccine in Patients With Primary Antiphospholipid Syndrome Open
Background : Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency of antiphospholipid antibodies (aPL). The recent reports of thrombosis associated with the adenovirus-based vaccines raises concern th…
View article: Immunogenicity and safety after SARS-CoV-2 vaccine in Primary Antiphospholipid Syndrome (PAPS)
Immunogenicity and safety after SARS-CoV-2 vaccine in Primary Antiphospholipid Syndrome (PAPS) Open
Immunogenicity data of COVID-19 vaccines for primary antiphospholipid syndrome (PAPS) is lacking.Recent reports of thrombosis with adenovirus-based vaccines raise concern in this predisposed population.Our aim was to evaluate the efficacy …
View article: Catastrophic antiphospholipid syndrome: A case with unusual findings revealed in autopsy and a brief literature update
Catastrophic antiphospholipid syndrome: A case with unusual findings revealed in autopsy and a brief literature update Open
Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening disease. It is characterized by multiple arterial and/or venous thrombotic events, including the microcirculation, occurring in a short period, and can affect any…